HSA | FSA CARDS ARE NOW ACCEPTED

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on hormones and fertility. Browse all Hormones & Fertility education

Two men start the same androgen-pathway protocol on the same day. Weeks later, their estrogen levels have diverged — significantly. Same protocol category, same starting point, different hormonal outcomes. The variable almost no provider checks first is CYP19A1, the gene that encodes aromatase and governs how aggressively your body converts testosterone to estrogen. If androgen-pathway optimization is part of your health strategy, your CYP19A1 variant is one of the most consequential genetic data points you probably don't yet have.

What Is CYP19A1 and What Does It Control?

CYP19A1 encodes aromatase, a cytochrome P450 enzyme responsible for converting androgens — primarily testosterone and androstenedione — into estrogens. In men, aromatase activity is not the enemy; some estradiol is essential for bone density, cardiovascular function, cognitive performance, and libido. The problem emerges at the extremes. Insufficient aromatization underserves estrogen-dependent pathways. Excessive aromatization shifts the androgen-estrogen ratio in ways that affect mood, body composition, breast tissue sensitivity, and hormonal signaling throughout the body.

The PlexusDx Precision Peptide Genetic Test analyzes CYP19A1 as part of 14 pathways, 49 peptides, and 150+ genetic insights — placing aromatase genetics within the Reproductive Health pathway and tracing its interactions with Energy Metabolism, Mood, and Muscle Growth across the full panel.

How CYP19A1 Variants Shape Aromatase Activity

CYP19A1 carries multiple well-characterized variants that influence both aromatase expression levels and enzymatic efficiency. Some variants are associated with elevated baseline aromatase activity — a higher proportion of circulating androgens is directed toward estradiol synthesis. Others correlate with lower baseline activity and a narrower conversion rate.

These are not binary states. Aromatase activity exists on a genetic continuum, and a man's CYP19A1 variant places him at a specific point on that spectrum before any protocol, supplement, or lifestyle intervention begins. That genetic baseline is the terrain your androgen-estrogen balance is working from — whether your provider knows it or not.

The Downstream Effects of Variable Aromatase Genetics

When androgen levels are increased through any pathway — exercise, dietary shifts, or androgen-pathway support protocols — aromatase has more substrate to work with. A man with high-activity CYP19A1 variants will convert a larger fraction of that increase into estradiol. A man with lower-activity variants will convert proportionally less. The clinical result: two men on identical androgen-pathway protocols arrive at different estrogen profiles, not because of their protocol, but because of their aromatase genetics.

This is why providers who monitor androgen protocols without knowing a patient's CYP19A1 status are working with an incomplete map. The genetic baseline doesn't change the protocol — it changes how the protocol is read and adjusted over time.

CYP19A1 and the Androgen-Pathway Pillar: What the Full Panel Reveals

CYP19A1 doesn't operate in isolation. It sits within a network of hormone-related genes that the Precision Peptide Genetic Test analyzes as a system — all 6 Reproductive Health insights working together as part of the broader Complete Guide to Genetic Men's Hormone Testing:

SHBG — sex hormone binding globulin variants affect how much free testosterone and estradiol actually circulate in bioavailable form. A man with high SHBG expression may show lower free estradiol despite active aromatase. SHBG Genetics: Why Your Free Testosterone Varies covers this interaction in detail.

AR (androgen receptor CAG repeats) — longer CAG repeat sequences reduce androgen receptor sensitivity. The same estradiol concentration reads differently to tissues depending on receptor responsiveness. What matters isn't just how much estrogen is produced — it's how sensitively tissues respond to it.

SRD5A2 — encodes 5-alpha reductase, the enzyme that routes testosterone toward DHT along a parallel metabolic pathway. SRD5A2 variants affect how androgens are partitioned between aromatization and 5-alpha reduction, shaping the overall hormonal output from any testosterone substrate.

ESR1 and ESR2 — estrogen receptor variants determine how tissues respond to the estradiol CYP19A1 produces. Downstream sensitivity is as genetically variable as the conversion step itself. Two men with identical CYP19A1 activity can experience the effects of estradiol very differently depending on their estrogen receptor genetics.

Together, these genes define the genetic architecture of androgen-estrogen balance in men. CYP19A1 alone is one lens. The full 6-insight Reproductive Health panel — within 14 total pathways — is the complete picture.

What Your CYP19A1 Results Can and Cannot Tell You

CYP19A1 results reveal your genetic tendency toward higher or lower aromatase activity. They are not a measurement of your current estradiol level — that requires blood testing. They are not a predictor of your response to any specific compound or protocol. What they deliver is a defined genetic baseline: the enzymatic terrain your androgen-estrogen balance occupies before protocols, body composition, lifestyle, and aging variables layer on top.

Genetics as a guide, not a guarantee. Your CYP19A1 variant is one precise input to a clinical picture your provider builds from multiple directions — genetics, blood biomarkers, symptoms, and goals together. The Precision Peptide Genetic Test delivers that genetic input with specificity: 6 Reproductive Health insights embedded in a 14-pathway, 150+ insight panel built for exactly this kind of precision approach.

The Precision Peptide Genetic Test analyzes how your genes influence hormone-related biological pathways. It does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol.

Ready to understand your aromatase genetics and where CYP19A1 fits in your hormone profile? Take the Precision Peptide Genetic Test

Frequently Asked Questions About CYP19A1 and Aromatase Genetics

What does CYP19A1 measure in the Precision Peptide Genetic Test?

CYP19A1 variants reveal your genetic baseline for aromatase activity — the enzyme that converts testosterone to estradiol in men. The Precision Peptide Genetic Test analyzes CYP19A1 as one of 6 Reproductive Health insights within 14 total pathways and 150+ genetic insights. Results show genetic tendency, not a current hormone measurement.

Do men with high CYP19A1 activity always have high estrogen?

Not automatically. CYP19A1 is one variable in a network that includes SHBG binding, androgen availability, ESR1/ESR2 receptor sensitivity, and body composition — adipose tissue is a major site of peripheral aromatization. High-activity variants increase conversion tendency, but actual estradiol levels depend on all variables together. Blood testing confirms where the balance lands.

How does CYP19A1 relate to other genes in the men's hormone panel?

CYP19A1 is one of 6 Reproductive Health insights the Precision Peptide Genetic Test analyzes together: SHBG governs hormone availability, AR (androgen receptor CAG repeats) governs androgen sensitivity, SRD5A2 routes androgens toward DHT rather than estradiol, and ESR1/ESR2 determine how tissues respond to estrogen produced. No single gene tells the complete story.

This article is part of the PlexusDx Education Hub. Browse all Hormones & Fertility education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.